Denali Ends DNL151 Parkinson's Program After LUMA Trial Miss; Q4 AVLAYAH Guidance $30-32M
DNLI sits 48% above its 52-week low of $13.75.
Summary
Denali is scrapping DNL151 for idiopathic Parkinson's disease after the LUMA trial failed to hit its endpoints — the clearest negative in this recap and a write-off of a lead pipeline asset. Offsetting that, Q3 AVLAYAH revenue came in at $17.8 million, above guidance, and the company guided Q4 to $30-32 million, a step up in the launch. The balance sheet carries roughly $1.01 billion in cash and securities, so funding is not the near-term issue. Also in the mix: Takeda terminated the DNL593 agreement and rights reverted to Denali with development continuing, zafinofusp alfa is targeted for a 2027 BLA under accelerated approval, and the DNL952 Pompe Phase 1 study is enrolling with initial data expected in 2027. Morgan Stanley kept Overweight and lifted its target to $42 from $40. Watch the 2027 readout slate across five TransportVehicle programs and the zafinofusp alfa filing.
At the time of this announcement, DNLI was trading at $20.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $13.75 to $27.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.